PFNX News and Press, Pfenex Inc. From 08/08/19

SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced the appo...

NDA for PF708 reached the FDA mid-cycle review milestone in May Positive Phase 1 results for PF743 (JZP-458) and Jazz advances the product to Pivotal Phase 2/3 Study Agreement with Arcellx Leverages Pfēnex Expression Technology® platform SAN DIEGO, Aug. 08, 2019 (G...

First Arcellx sparX protein successfully completed process development using Pf ēnex Expression Technology ® platform Second sparX program initiated by Arcellx SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) and Arcellx, Inc. today annou...

SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced that i...

Point Roberts, WA and Delta, BC - June 14, 2019 (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week�s additions to its global stock directories in mining, tech, biotech and ride sharing. New mining companies are all li...

As the chart below illustrates, Antares Pharma ( ATRS ) stock has been down and under pressure since the FDA approval of Clarus Therapeutics' TRT drug Jatenzo on March 28, which gives an indication of lower investor sentiment and expectations. (Courtesy StockCharts.com) After reaching an i...

SAN DIEGO, June 05, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology ® to improve protein therapies for unmet patient needs, announced today that ...

Point Roberts, WA and Delta, BC - June 4, 2019 (Investorideas.com Newswire) Investorideas.com, a leading investor news resource covering biotechnology and pharmaceutical stocks releases a sector snapshot reporting on the continued growth in OTC analgesics as consumers look for more affordable an...

The EMA has accepted Pfenex's (NYSEMKT: PFNX ) Marketing Authorization Application (MAA) submitted by its partner Alvogen for PF708 (teriparatide), a therapeutic equivalent in the treatment of osteoporosis to Forteo. More news on: Pfenex Inc., Healthcare stocks news, Read more ...

SAN DIEGO, May 30, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) and Alvogen today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) submitted by our partner Alvogen for PF708 (teriparatide).  The product is propo...